CN102311449B - 棉酚衍生物在制备抗肿瘤药物中的应用 - Google Patents
棉酚衍生物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN102311449B CN102311449B CN2010102193119A CN201010219311A CN102311449B CN 102311449 B CN102311449 B CN 102311449B CN 2010102193119 A CN2010102193119 A CN 2010102193119A CN 201010219311 A CN201010219311 A CN 201010219311A CN 102311449 B CN102311449 B CN 102311449B
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- gossypol
- bcl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)([C@@]1*)SC(C2PC)N1C2=O Chemical compound CC(C)([C@@]1*)SC(C2PC)N1C2=O 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/10—Modification of an amino radical directly attached in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/04—Preparation
- C07D499/14—Preparation of salts
- C07D499/16—Preparation of salts of alkali or alkaline earth metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
Abstract
Description
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102193119A CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
PCT/CN2011/076482 WO2012000421A1 (zh) | 2010-07-02 | 2011-06-28 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102193119A CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102311449A CN102311449A (zh) | 2012-01-11 |
CN102311449B true CN102311449B (zh) | 2013-11-20 |
Family
ID=45401394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102193119A Expired - Fee Related CN102311449B (zh) | 2010-07-02 | 2010-07-02 | 棉酚衍生物在制备抗肿瘤药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102311449B (zh) |
WO (1) | WO2012000421A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690326B (zh) * | 2012-05-29 | 2014-04-02 | 武汉大学 | 具有抗艾滋病毒活性的棉酚衍生物及其制备 |
CN103265560B (zh) * | 2013-05-17 | 2016-05-04 | 中国科学院上海高等研究院 | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 |
CN104817472B (zh) * | 2015-03-25 | 2016-08-24 | 武汉大学 | 一种新型棉酚衍生物及其制备方法和抗肿瘤应用 |
CN105503627B (zh) * | 2015-12-10 | 2017-10-03 | 武汉大学 | 一种新型棉酚希夫碱衍生物及其制备方法与应用 |
US9758503B1 (en) * | 2017-03-27 | 2017-09-12 | Shaanxi University Of Science And Technology | Coumarin-gossypol derivatives with antitumor activities and a method of preparing the same |
CN107417580A (zh) * | 2017-09-12 | 2017-12-01 | 陕西科技大学 | 一类具有抗肿瘤活性的棉酚‑l‑精氨酸席夫碱类化合物及其合成方法 |
US9758486B1 (en) * | 2017-03-27 | 2017-09-12 | Shaanxi University Of Science And Technology | Edaravone-gossypol derivatives with antitumor activities and a method of preparing the same |
CN107573318A (zh) * | 2017-09-12 | 2018-01-12 | 陕西科技大学 | 一种具抗肿瘤活性的新型棉酚席夫碱类衍生物及其合成方法 |
CN113214066A (zh) * | 2020-02-04 | 2021-08-06 | 中国医学科学院药物研究所 | 棉酚晶ii型物质及制备方法和其组合物与用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1887838A (zh) * | 2006-07-14 | 2007-01-03 | 中国科学院上海有机化学研究所 | 酸和丙酮水溶液一步法制备酸性棉酚衍生物的方法 |
CN1911215A (zh) * | 2003-06-11 | 2007-02-14 | 中国科学院动物研究所 | 棉酚及其衍生物在制备治疗白血病药物中的应用 |
WO2009045410A1 (en) * | 2007-10-01 | 2009-04-09 | Ascenta Therapeutics, Inc. | Process for preparing r-gossypol l-phenylalaninol dienamine |
-
2010
- 2010-07-02 CN CN2010102193119A patent/CN102311449B/zh not_active Expired - Fee Related
-
2011
- 2011-06-28 WO PCT/CN2011/076482 patent/WO2012000421A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911215A (zh) * | 2003-06-11 | 2007-02-14 | 中国科学院动物研究所 | 棉酚及其衍生物在制备治疗白血病药物中的应用 |
CN1887838A (zh) * | 2006-07-14 | 2007-01-03 | 中国科学院上海有机化学研究所 | 酸和丙酮水溶液一步法制备酸性棉酚衍生物的方法 |
WO2009045410A1 (en) * | 2007-10-01 | 2009-04-09 | Ascenta Therapeutics, Inc. | Process for preparing r-gossypol l-phenylalaninol dienamine |
Non-Patent Citations (6)
Title |
---|
1H- and 13C-NMR, FTIR, UV-VIS,ESI-MS, and PM5 Studies as Well as Emission Properties of a New Schiff Base of Gossypol with 5-Methoxytryptamine and a New Hydrazone of Gossypol with Dansylhydrazine;Piotr Przybylski et al;《Biopolymers》;20060314;第82卷;521-535 * |
Jun Wei et al.Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists.《Cancer Letters》.2009,第273卷107-113. |
Piotr Przybylski et al.1H- and 13C-NMR, FTIR, UV-VIS,ESI-MS, and PM5 Studies as Well as Emission Properties of a New Schiff Base of Gossypol with 5-Methoxytryptamine and a New Hydrazone of Gossypol with Dansylhydrazine.《Biopolymers》.2006,第82卷521-535. |
Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists;Jun Wei et al;《Cancer Letters》;20091231;第273卷;107-113 * |
张献清 等.新型棉酚衍生物ApoG2对人前列腺癌PC - 3移植瘤生长的抑制.《现代肿瘤医学》.2010,第18卷(第2期),259-263. |
张献清 等.新型棉酚衍生物ApoG2对人前列腺癌PC- 3移植瘤生长的抑制.《现代肿瘤医学》.2010,第18卷(第2期),259-263. * |
Also Published As
Publication number | Publication date |
---|---|
CN102311449A (zh) | 2012-01-11 |
WO2012000421A1 (zh) | 2012-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102311449B (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
CN103265560A (zh) | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 | |
PL199781B1 (pl) | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania | |
CN105985323A (zh) | 新型表皮生长因子受体抑制剂及其应用 | |
CN106749089A (zh) | 新型氟代噻唑腙类化合物的制备及其在抗肿瘤药物中的应用 | |
CN104926792B (zh) | 甲硝唑衍生物及其制备方法和用途 | |
JP2015501792A (ja) | ベンジリデンベンゾヒドラジドを用いた卵巣がんの治療 | |
CN112707833A (zh) | 组蛋白去乙酰酶抑制剂及其制备和应用 | |
CN103965175B (zh) | 4‑(取代苯氨基)喹唑啉类化合物、其制备方法及应用 | |
CN101429175B (zh) | 一种具有抗肿瘤活性的紫苏醇衍生物及其用途 | |
JP6404220B2 (ja) | テアニン誘導体とカルボン酸クマリン誘導体との縮合生成物、その中間体、調製方法、及びその使用 | |
CN104402861A (zh) | 苯磺酰胺衍生物、制备方法及治疗用途 | |
WO2018014368A1 (zh) | 一种水溶性靛红衍生物及其制备方法与应用 | |
CN110590778B (zh) | 3,10二对甲氧基苯基6,12二氮杂四高立方烷类化合物及合成方法和药物组合物 | |
JP2014533273A (ja) | 2−アミノ−4H−ナフト[1,2−b]ピラン−3−カルボニトリルを用いた卵巣がんの治療 | |
CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
CN107325031A (zh) | 一种含硒二苯甲酮及其衍生物和制备方法以及在制备抗肿瘤药物中的应用 | |
CN102267952A (zh) | 喹唑啉类化合物、其制备方法和用途 | |
CN106361752A (zh) | 氟哌噻吨的新用途 | |
CN108570043A (zh) | 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用 | |
CN108570027A (zh) | 一种用于治疗肿瘤的选择性pi3k抑制剂 | |
CN103772262B (zh) | 一种具有抗肿瘤活性的异邻苯二甲酰亚胺类化合物及其应用 | |
CN108864074A (zh) | 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用 | |
CN105884764B (zh) | 新型8,10-去二氮杂-n5-酰基四氢叶酸类化合物作为抗肿瘤药物的应用 | |
CN114874108A (zh) | 一种百里醌衍生物及其在制备ampk激活剂和治疗乳腺癌的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ADVANCED RESEARCH INSTITUTE, CHINESE ACAD Free format text: FORMER OWNER: SHANGHAI ZHONGKE INSTITUTE FOR ADVANCED STUDY Effective date: 20131023 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131023 Address after: 200031 No. 320, Yueyang Road, Shanghai Applicant after: Shanghai Institute of life Sciences, Chinese Academy of Sciences Applicant after: Shanghai Advanced Research Institute, Chinese Academy of Sciences Address before: 200031 No. 320, Yueyang Road, Shanghai Applicant before: Shanghai Institute of life Sciences, Chinese Academy of Sciences Applicant before: Shanghai Zhongke Institute for Advanced Study |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160824 Address after: 201203 Shanghai city Pudong New Area Hartcourt Road No. 99 Patentee after: Shanghai Advanced Research Institute, Chinese Academy of Sciences Address before: 200031 No. 320, Yueyang Road, Shanghai Patentee before: Shanghai Institute of life Sciences, Chinese Academy of Sciences Patentee before: Shanghai Advanced Research Institute, Chinese Academy of Sciences |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131120 Termination date: 20200702 |